• Stephanie A Lee-Felker, Leena Tekchandani, Mariam Thomas, Esha Gupta, Denise Andrews-Tang, Antoinette Roth, James Sayre, and Guita Rahbar.
• From the Department of Radiological Sciences, David Geffen School of Medicine at UCLA, 200 UCLA Medical Plaza, Room 165-53, Los Angeles, CA 90095 (S.A.L.F.); Department of Radiological Sciences, Santa Ana-Tustin Radiology Medical Group, Santa Ana, Calif (L.T.); Department of Radiological Sciences, Olive View-UCLA Medical Center, Los Angeles, Calif (M.T., D.A.T., A.R., E.G., G.R.); and Department of Biostatistics, UCLA Fielding School of Public Health, Los Angeles, Calif (J.S.).
• Radiology. 2017 Nov 1; 285 (2): 389-400.

AbstractPurpose To compare the diagnostic performances of contrast material-enhanced spectral mammography and breast magnetic resonance (MR) imaging in the detection of index and secondary cancers in women with newly diagnosed breast cancer by using histologic or imaging follow-up as the standard of reference. Materials and Methods This institutional review board-approved, HIPAA-compliant, retrospective study included 52 women who underwent breast MR imaging and contrast-enhanced spectral mammography for newly diagnosed unilateral breast cancer between March 2014 and October 2015. Of those 52 patients, 46 were referred for contrast-enhanced spectral mammography and targeted ultrasonography because they had additional suspicious lesions at MR imaging. In six of the 52 patients, breast cancer had been diagnosed at an outside institution. These patients were referred for contrast-enhanced spectral mammography and targeted US as part of diagnostic imaging. Images from contrast-enhanced spectral mammography were analyzed by two fellowship-trained breast imagers with 2.5 years of experience with contrast-enhanced spectral mammography. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value were calculated for both imaging modalities and compared by using the Bennett statistic. Results Fifty-two women with 120 breast lesions were included for analysis (mean age, 50 years; range, 29-73 years). Contrast-enhanced spectral mammography had similar sensitivity to MR imaging (94% [66 of 70 lesions] vs 99% [69 of 70 lesions]), a significantly higher PPV than MR imaging (93% [66 of 71 lesions] vs 60% [69 of 115 lesions]), and fewer false-positive findings than MR imaging (five vs 45) (P < .001 for all results). In addition, contrast-enhanced spectral mammography depicted 11 of the 11 secondary cancers (100%) and MR imaging depicted 10 (91%). Conclusion Contrast-enhanced spectral mammography is potentially as sensitive as MR imaging in the evaluation of extent of disease in newly diagnosed breast cancer, with a higher PPV. © RSNA, 2017.

15 keywords...

hide…